ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Days Sales Outstanding : 13.08 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Days Sales Outstanding?

ImmuneOnco Biopharmaceuticals (Shanghai)'s average Accounts Receivable for the six months ended in Dec. 2023 was HK$0.02 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s Revenue for the six months ended in Dec. 2023 was HK$0.33 Mil. Hence, ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the six months ended in Dec. 2023 was 13.08.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding or its related term are showing as below:

HKSE:01541' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47 Med: 35.22 Max: 50.6
Current: 34.89

During the past 3 years, ImmuneOnco Biopharmaceuticals (Shanghai)'s highest Days Sales Outstanding was 50.60. The lowest was 2.47. And the median was 35.22.

HKSE:01541's Days Sales Outstanding is ranked better than
81.91% of 890 companies
in the Biotechnology industry
Industry Median: 72.665 vs HKSE:01541: 34.89

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding declined from Dec. 2022 (107.18) to Dec. 2023 (13.08).

ImmuneOnco Biopharmaceuticals (Shanghai) Days Sales Outstanding Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Days Sales Outstanding Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Days Sales Outstanding

2.47

35.22

50.60

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	-	15.39	107.18	75.72	13.08

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.074	+	0.043)	/	2 )	/	0.422	*	365
=	0.0585					/	0.422	*	365
=	50.60

ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.004	+	0.043)	/	2 )	/	0.328	*	365 / 2
=	0.0235					/	0.328	*	365 / 2
=	13.08

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

ImmuneOnco Biopharmaceuticals (Shanghai) Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines